Individuals with anxiety will experience frequent or chronic excessive worry, nervousness, a sense of unease, and distress, which result in functional impairment.\(^1\) Frequently, anxiety is accompanied by restlessness or muscle tension. Generalized anxiety disorder is one of the most common psychiatric diagnoses in the United States and has a prevalence of 2% to 6% globally.\(^2\) Although research has been conducted regarding anxiety’s pathogenesis, to date a firm consensus on its etiology has not been reached.\(^3\) It is likely multifactorial, with environmental and biologic components.

One area of focus has been neurotransmitters and the possible role they play in the pathogenesis of anxiety. Specifically, the monoamine neurotransmitters have been implicated in the clinical manifestations of anxiety. Among the amines, normal roles include stimulating the autonomic nervous system and regulating numerous cognitive phenomena, such as volition and emotion. Many psychiatric medications modify aminergic transmission, and many current anxiety medications target amine neurotransmitters. Medications that target histamine, serotonin, norepinephrine, and dopamine all play a role in treating anxiety.

In this article, we focus on serotonin (5-hydroxytryptamine, 5-HT) as a mediator of anxiety and on excessive synaptic 5-HT as the cause of anxiety. We discuss how 5-HT-mediated anxiety can be identified and offer some solutions for its treatment.

The amine neurotransmitters

There are 6 amine neurotransmitters in the CNS. These are derived from tyrosine (dopamine [DA], norepinephrine [NE], and epinephrine), histidine (histamine), and tryptophan (serotonin [5-HT] and melatonin). In addition to their physiologic actions, amines have been implicated in both acute and chronic anxiety. Excessive DA stimulation has been linked with fear\(^4,5\); NE elevations are central to hypervigilance and hyperarousal of posttraumatic stress disorder\(^6\); and histamine may mediate emotional memories involved in fear and anxiety.\(^7\) Understanding the normal function of 5-HT will aid in understanding its potential problematic role (Box,\(^8-18\) page 38).

How serotonin-mediated anxiety presents

“Anxiety” is a collection of signs and symptoms that likely represent multiple processes and have the common characteristic of being subjectively unpleasant, with a subjective wish for the feeling to end. The expression of anxiety disorders is quite diverse and ranges from brief episodes such

Dr. Abell is a PGY-1 Psychiatry Resident, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, Kentucky. Dr. El-Mallakh is Professor and Director, Mood Disorders Research Program, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, Kentucky.

Disclosures

Dr. Abell reports no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products. Dr. El-Mallakh is a speaker for Eisai, Intracellular Therapies, Indivior, Janssen, Lundbeck, Noven, Otsuka, Sunovion, and Teva.

doi: 10.12788/cp.0168

Rif S. El-Mallakh, MD
Department Editor

Discuss this article at www.facebook.com/MDedgePsychiatry

Current Psychiatry
Vol. 20, No. 11 | 37
Towards this end, it is important to investigate the phenomenon of serotonin-mediated anxiety.

Because clinicians are familiar with reductions of anxiety as selective serotonin reuptake inhibitors (SSRIs) increase 5-HT levels in the synapse, it is difficult to conceptualize serotonin-mediated anxiety. However, many of the effects at postsynaptic 5-HT receptors may be biphasic. Serotonin-mediated anxiety appears to occur when levels of 5-HT (or stimulation of 5-HT receptors) are particularly high. This is most frequently seen in patients who genetically have high synaptic 5-HT (by virtue of the short form of the 5-HT transporter), whose synaptic 5-HT is further increased by treatment with an SSRI, and who are experiencing a stressor that yet further increases their synaptic 5-HT. However, it may occur in some individuals with only 2 of these 3 conditions.
Clinically, individuals with serotonin-mediated anxiety will usually appear calm. The anxiety they are experiencing is not exhibited in any way in the motor system (ie, they do not appear restless, do not pace, muscle tone is not increased, etc.). However, they will generally complain of an internal agitation, a sense of a negative internal energy. Frequently, they will use descriptions such as “I feel I could jump out of my skin.” As previously mentioned, this is usually in the setting of some environmental stress, in addition to either a pharmacologic (SSRI) or genetic (short form of the 5-HT transporter) reason for increasing synaptic 5-HT, or both.

Almost always, interventions that block multiple postsynaptic 5-HT receptors or discontinuation of the SSRI (if applicable) will alleviate the anxiety, quickly or more slowly, respectively. Sublingual asenapine, which at low doses can block 5-HT2C (Ki = 0.03 nM), 5-HT2A (Ki = 0.07 nM), 5-HT7 (Ki = 0.11 nM), 5-HT2B (Ki = 0.18 nM), and 5-HT6 (Ki = 0.25 nM),25,26 and which will produce peak plasma levels within 10 minutes,27 usually is quite effective.28

A key difference: No motor system involvement
What distinguishes 5-HT from the other amine transmitters as a mediator of anxiety is the lack of involvement of the motor system. Multiple studies in rats illustrate that exogenously augmenting 5-HT has no effect on levels of locomotor activity. Dopamine depletion is well-characterized in the motor dysfunction of Parkinson’s disease, and DA excess can cause repetitive, stereotyped movements, such as seen in tardive dyskinesia or Huntington’s disease.8 In humans, serotonin-mediated anxiety is usually without a motoric component; patients appear calm but complain of extreme anxiety or agitation. Agitation has been reported after initiation of an SSRI,29 and is more likely to occur in patients with the short form of the 5-HT transporter.30 Motoric activation has been reported in some of these studies, but does not seem to cluster with the complaint of agitation.29 The reduced number of available transporters means a chronic steady-state elevation of serotonin, because less serotonin is being removed from the synapse after it is released. This is one of the reasons patients with the short form of the 5-HT transporter may be more susceptible to serotonin-mediated anxiety.

What you need to keep in mind
Pharmacologic treatment of anxiety begins with an SSRI, a serotonin-norepinephrine reuptake inhibitor (SNRI), or buspirone. Second-line treatments include hydroxyzine, gabapentin, pregabalin, and quetiapine.3,31 However, clinicians need to be aware that a fraction of their patients will report anxiety that will not have any external manifestations, but will be experienced as an unpleasant internal energy. These patients may report an increase in their anxiety levels when started on an SSRI or SNRI.29,30 This anxiety is most likely mediated by increases of synaptic 5-HT. This occurs because many serotonergic receptors may have a biphasic response, so that too much stimulation is experienced as excessive internal energy.16-18 In such patients, blockade of key 5-HT receptors may reduce that internal agitation. The advantage of recognizing serotonin-mediated anxiety is that one can specifically tailor treatment to address the patient’s specific physiology.

It is important to note that the anxiolytic effect of asenapine is specific to patients with serotonin-mediated anxiety. Unlike quetiapine, which is effective as augmentation therapy in generalized anxiety disorder,31 asenapine does not appear to reduce anxiety in patients with schizophrenia32 or borderline personality disorder33 when administered for other reasons. However, it may reduce anxiety in patients with the short form of the 5-HT transporter.30,34

References
the SSRI will alleviate 5-HT receptors or postsynaptic block multiple interventions that Clinical Point


**Related Resource**


**Drug Brand Names**

- Asenapine - Saphris, Saphrisos
- Selegidone - Neurontin
- Gabapentin - Neurontin
- Hydroxyzine - Vistaril
- Quetiapine - Seroquel
- Trazodone - Oleptro
- Pregabalin - Lyrica
- Gabapentin - Lyrica
- Saphris
- Quetiapine
- Seroquel
- Pregabalin
- Oleptro
- Vistaril
- Asenapine
- Saphris
- Gabapentin
- Hydroxyzine
- Quetiapine
- Trazodone
- Pregabalin
- Oleptro
- Vistaril
- Asenapine

**Clinical Point**

Interventions that block multiple postsynaptic 5-HT receptors or discontinuation of the SSRI will alleviate the anxiety

**Bottom Line**

Serotonin-mediated anxiety occurs when levels of synaptic serotonin (5-HT) are high. Patients with serotonin-mediated anxiety appear calm but will report experiencing an unpleasant internal energy. Interventions that block multiple postsynaptic 5-HT receptors or discontinuation of a selective serotonin reuptake inhibitor (if applicable) will alleviate the anxiety.